Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer.

De Laere B, Oeyen S, Mayrhofer M, Whitington T, van Dam PJ, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert EG, De Maeseneer D, Strijbos M, Bols A, Fransis K, Beije N, de Kruijff IE, van Dam V, Brouwer A, Goossens D, Heyrman L, Van den Eynden GG, Rutten A, Del Favero J, Rantalainen M, Rajan P, Sleijfer S, Ullén A, Yachnin J, Grönberg H, Van Laere SJ, Lindberg J, Dirix LY.

Clin Cancer Res. 2018 Sep 12. pii: clincanres.1943.2018. doi: 10.1158/1078-0432.CCR-18-1943. [Epub ahead of print]

PMID:
30209161
2.

Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.

Roseweir AK, Bennett L, Dickson A, Cheng K, Quintayo MA, Bayani J, McMillan DC, Horgan PG, van de Velde CJH, Seynaeve C, Hasenburg A, Kieback DG, Markopoulos C, Dirix LY, Rea DW, Mallon EA, Bartlett JMS, Edwards J.

J Natl Cancer Inst. 2018 Jun 1;110(6):616-627. doi: 10.1093/jnci/djx255.

PMID:
29917140
3.

Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.

Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ.

Eur J Cancer. 2018 Aug;99:1-8. doi: 10.1016/j.ejca.2018.04.009. Epub 2018 Jun 6.

PMID:
29885375
4.

Adjuvant aromatase inhibition: more options for patients.

Dirix LY.

Lancet Oncol. 2018 Apr;19(4):431-432. doi: 10.1016/S1470-2045(18)30155-4. Epub 2018 Feb 23. No abstract available.

PMID:
29482984
5.

An In-Depth Evaluation of the Validity and Logistics Surrounding the Testing of AR-V7 mRNA Expression in Circulating Tumor Cells.

Sieuwerts AM, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort CM, Van M, Prager WJC, De Laere B, Beije N, Hamberg P, Westgeest HM, Tascilar M, Dirix LY, Onstenk W, de Wit R, Lolkema MP, Mathijssen RHJ, Martens JWM, Sleijfer S.

J Mol Diagn. 2018 May;20(3):316-325. doi: 10.1016/j.jmoldx.2018.01.008. Epub 2018 Feb 21.

PMID:
29474983
6.

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.

Beije N, Sieuwerts AM, Kraan J, Van NM, Onstenk W, Vitale SR, van der Vlugt-Daane M, Dirix LY, Brouwer A, Hamberg P, de Jongh FE, Jager A, Seynaeve CM, Jansen MPHM, Foekens JA, Martens JWM, Sleijfer S.

Mol Oncol. 2018 Jan;12(1):48-57. doi: 10.1002/1878-0261.12147. Epub 2017 Nov 17.

7.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

8.

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis.

van Dam PJ, van der Stok EP, Teuwen LA, Van den Eynden GG, Illemann M, Frentzas S, Majeed AW, Eefsen RL, Coebergh van den Braak RRJ, Lazaris A, Fernandez MC, Galjart B, Laerum OD, Rayes R, Grünhagen DJ, Van de Paer M, Sucaet Y, Mudhar HS, Schvimer M, Nyström H, Kockx M, Bird NC, Vidal-Vanaclocha F, Metrakos P, Simoneau E, Verhoef C, Dirix LY, Van Laere S, Gao ZH, Brodt P, Reynolds AR, Vermeulen PB.

Br J Cancer. 2017 Nov 7;117(10):1427-1441. doi: 10.1038/bjc.2017.334. Epub 2017 Oct 5.

PMID:
28982110
9.

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.

Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH.

Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18.

PMID:
28732650
10.

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC).

Joglekar-Javadekar M, Van Laere S, Bourne M, Moalwi M, Finetti P, Vermeulen PB, Birnbaum D, Dirix LY, Ueno N, Carter M, Rains J, Ramachandran A, Bertucci F, van Golen KL.

Neoplasia. 2017 Jul;19(7):564-573. doi: 10.1016/j.neo.2017.03.002. Epub 2017 Jun 10.

11.

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.

Beije N, Onstenk W, Kraan J, Sieuwerts AM, Hamberg P, Dirix LY, Brouwer A, de Jongh FE, Jager A, Seynaeve CM, Van NM, Foekens JA, Martens JW, Sleijfer S.

Neoplasia. 2016 Nov;18(11):647-653. doi: 10.1016/j.neo.2016.08.007. Epub 2016 Oct 17.

12.

Increased Angiogenesis and Lymphangiogenesis in Metastatic Sentinel Lymph Nodes Is Associated With Nonsentinel Lymph Node Involvement and Distant Metastasis in Patients With Melanoma.

Pastushenko I, Van den Eynden GG, Vicente-Arregui S, Prieto-Torres L, Alvarez-Alegret R, Querol I, Dirix LY, Carapeto FJ, Vermeulen PB, Van Laere SJ.

Am J Dermatopathol. 2016 May;38(5):338-46. doi: 10.1097/DAD.0000000000000488.

PMID:
26909582
13.

An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.

Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MP, Gratama JW, Foekens JA, Martens JW, Berns EM, Sleijfer S.

BMC Cancer. 2016 Feb 18;16:123. doi: 10.1186/s12885-016-2155-y.

14.

Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial.

Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW.

Arch Pathol Lab Med. 2016 Jan;140(1):66-74. doi: 10.5858/arpa.2014-0599-OA.

PMID:
26717057
15.

Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma.

Pastushenko I, Vermeulen PB, Vicente-Arregui S, Van den Eynden GG, Alvarez-Alegret R, Querol I, Rutten A, Carapeto FJ, Dirix LY, Van Laere S.

J Cutan Pathol. 2015 Oct;42(10):699-711. doi: 10.1111/cup.12571. Epub 2015 Sep 11.

PMID:
26264662
16.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
17.

Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial.

Fontein DB, Klinten Grand M, Nortier JW, Seynaeve C, Meershoek-Klein Kranenbarg E, Dirix LY, van de Velde CJ, Putter H.

Ann Oncol. 2015 Jun;26(6):1254-62. doi: 10.1093/annonc/mdv146. Epub 2015 Apr 10.

PMID:
25862439
18.

Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.

van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2015 Feb 18;17:21. doi: 10.1186/s13058-015-0526-y. Review.

19.

Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.

Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CH, Bolt-de Vries JB, Peeters DJ, Hamberg P, Seynaeve C, Jager A, de Jongh FE, Smid M, Dirix LY, Kehrer DF, van Galen A, Ramirez-Moreno R, Kraan J, Van M, Gratama JW, Martens JW, Foekens JA, Sleijfer S.

Cancer Lett. 2015 Jun 28;362(1):36-44. doi: 10.1016/j.canlet.2015.03.020. Epub 2015 Mar 19.

PMID:
25797316
20.

Melanomas arising on skin with chronic sun-induced damage exhibit low degree of angiogenesis and lymphangiogenesis.

Pastushenko I, Vicente-Arregui S, Van den Eynden GG, Gracia-Cazaña T, Carapeto FJ, Alvarez-Alegret R, Dirix LY, Vermeulen PB, Van Laere S.

Am J Dermatopathol. 2015 Jun;37(6):451-4. doi: 10.1097/DAD.0000000000000265.

PMID:
25747811
21.

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

Diéras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roché H, Sánchez-Rovira P, Pienkowski T, Seguí Palmer MÁ, Li A, Sun YN, Pickett CA, Slamon DJ.

Breast. 2015 Jun;24(3):182-90. doi: 10.1016/j.breast.2014.11.003. Epub 2015 Mar 5.

PMID:
25747197
22.

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.

Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S.

Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3.

PMID:
25471333
23.

Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer.

Peeters DJ, Brouwer A, Van den Eynden GG, Rutten A, Onstenk W, Sieuwerts AM, Van Laere SJ, Huget P, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Cancer Lett. 2015 Jan 28;356(2 Pt B):872-9. doi: 10.1016/j.canlet.2014.10.039. Epub 2014 Nov 4.

PMID:
25449778
24.

Tumor stromal phenotypes define VEGF sensitivity--letter.

Van den Eynden GG, Bird NC, Dirix LY, Eefsen RL, Gao ZH, Høyer-Hansen G, Illemann M, Majeed AW, Metrakos P, Reynolds AR, Vainer B, van Dam PJ, Van Laere SJ, Vermeulen PB, Vidal-Vanaclocha F, Brodt P; Liver Metastasis Research Network.

Clin Cancer Res. 2014 Oct 1;20(19):5140. doi: 10.1158/1078-0432.CCR-14-0158. No abstract available.

25.

Bevacizumab beyond progression in breast cancer.

Dirix LY, Reynolds AR.

Lancet Oncol. 2014 Oct;15(11):1190-1. doi: 10.1016/S1470-2045(14)70454-1. Epub 2014 Sep 28. No abstract available.

PMID:
25273341
26.

Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.

Pastushenko I, Vermeulen PB, Van den Eynden GG, Rutten A, Carapeto FJ, Dirix LY, Van Laere S.

Br J Dermatol. 2014 Aug;171(2):220-33. doi: 10.1111/bjd.12973. Epub 2014 Jul 26. Review.

PMID:
24641095
27.

A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples.

Marsan M, Van den Eynden G, Limame R, Neven P, Hauspy J, Van Dam PA, Vergote I, Dirix LY, Vermeulen PB, Van Laere SJ.

PLoS One. 2014 Feb 21;9(2):e89262. doi: 10.1371/journal.pone.0089262. eCollection 2014.

28.

Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.

Liu NQ, Stingl C, Look MP, Smid M, Braakman RB, De Marchi T, Sieuwerts AM, Span PN, Sweep FC, Linderholm BK, Mangia A, Paradiso A, Dirix LY, Van Laere SJ, Luider TM, Martens JW, Foekens JA, Umar A.

J Natl Cancer Inst. 2014 Feb;106(2):djt376. doi: 10.1093/jnci/djt376. Epub 2014 Jan 7.

29.

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.

Peeters DJ, van Dam PJ, Van den Eynden GG, Rutten A, Wuyts H, Pouillon L, Peeters M, Pauwels P, Van Laere SJ, van Dam PA, Vermeulen PB, Dirix LY.

Br J Cancer. 2014 Jan 21;110(2):375-83. doi: 10.1038/bjc.2013.743. Epub 2013 Dec 24.

30.

Blood microvessel density, lymphatic microvessel density and lymphatic invasion in predicting melanoma metastases: systematic review and meta-analysis.

Pastushenko I, Vermeulen PB, Carapeto FJ, Van den Eynden G, Rutten A, Ara M, Dirix LY, Van Laere S.

Br J Dermatol. 2014 Jan;170(1):66-77. doi: 10.1111/bjd.12688. Review.

PMID:
24134623
31.

Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial.

Bartlett JM, Brookes CL, Piper T, van de Velde CJ, Stocken D, Lyttle N, Hasenburg A, Quintayo MA, Kieback DG, Putter H, Markopoulos C, Kranenbarg EM, Mallon EA, Dirix LY, Seynaeve C, Rea DW.

Br J Cancer. 2013 Oct 29;109(9):2453-61. doi: 10.1038/bjc.2013.609. Epub 2013 Oct 3.

32.

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, Reed N, Dark G, Fracasso PM, Ibrahim EN, Armenio VA, Duska L, Poole C, Gennigens C, Dirix LY, Leung AC, Zhao C, Soufi-Mahjoubi R, Rustin G.

J Clin Oncol. 2013 Nov 10;31(32):4060-6. doi: 10.1200/JCO.2012.45.1278. Epub 2013 Sep 30.

33.

Trastuzumab emtansine in breast cancer.

Dirix LY, Rutten A, Huget P, Dirix M.

Expert Opin Biol Ther. 2013 Apr;13(4):607-14. doi: 10.1517/14712598.2013.778238. Review.

PMID:
23477731
34.

Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting.

Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothé F, Ignatiadis M, Sieuwerts AM, Lambrechts D, Rutten A, van Dam PA, Pauwels P, Peeters M, Vermeulen PB, Dirix LY.

Br J Cancer. 2013 Apr 2;108(6):1358-67. doi: 10.1038/bjc.2013.92. Epub 2013 Mar 7.

35.

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR, Scherer SJ.

Br J Cancer. 2013 Mar 19;108(5):1052-60. doi: 10.1038/bjc.2013.69. Epub 2013 Feb 19.

36.

The interaction between ER and NFκB in resistance to endocrine therapy.

Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2012 Aug 31;14(4):212. doi: 10.1186/bcr3196. Review.

37.

Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.

van de Water W, Fontein DB, van Nes JG, Bartlett JM, Hille ET, Putter H, Robson T, Liefers GJ, Roumen RM, Seynaeve C, Dirix LY, Paridaens R, Kranenbarg EM, Nortier JW, van de Velde CJ.

Eur J Cancer. 2013 Jan;49(2):297-304. doi: 10.1016/j.ejca.2012.07.026. Epub 2012 Sep 3.

38.

Regulation of inflammatory breast cancer cell invasion through Akt1/PKBα phosphorylation of RhoC GTPase.

Lehman HL, Van Laere SJ, van Golen CM, Vermeulen PB, Dirix LY, van Golen KL.

Mol Cancer Res. 2012 Oct;10(10):1306-18. doi: 10.1158/1541-7786.MCR-12-0173. Epub 2012 Aug 15.

39.

Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.

Fontein DB, Houtsma D, Hille ET, Seynaeve C, Putter H, Meershoek-Klein Kranenbarg E, Guchelaar HJ, Gelderblom H, Dirix LY, Paridaens R, Bartlett JM, Nortier JW, van de Velde CJ; Dutch TEAM Steering Committee.

Ann Oncol. 2012 Dec;23(12):3091-7. doi: 10.1093/annonc/mds204. Epub 2012 Aug 2.

PMID:
22865782
40.

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.

Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B.

Cancer. 2012 Dec 15;118(24):6152-61. doi: 10.1002/cncr.27632. Epub 2012 Jun 12.

41.

The histological growth pattern of colorectal cancer liver metastases has prognostic value.

Van den Eynden GG, Bird NC, Majeed AW, Van Laere S, Dirix LY, Vermeulen PB.

Clin Exp Metastasis. 2012 Aug;29(6):541-9. doi: 10.1007/s10585-012-9469-1. Epub 2012 Apr 3.

PMID:
22476470
42.

Inflammatory HER2-positive breast cancer.

Dirix LY, Vermeulen PB.

Lancet Oncol. 2012 Apr;13(4):324-6. doi: 10.1016/S1470-2045(12)70081-5. Epub 2012 Feb 28. No abstract available.

PMID:
22377127
43.

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.

van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ.

Breast Cancer Res. 2012 Feb 21;14(1):R34.

44.

A phase II study of the combination of endocrine treatment and bortezomib in patients with endocrine-resistant metastatic breast cancer.

Trinh XB, Sas L, Van Laere SJ, Prové A, Deleu I, Rasschaert M, Van de Velde H, Vinken P, Vermeulen PB, Van Dam PA, Wojtasik A, De Mesmaeker P, Tjalma WA, Dirix LY.

Oncol Rep. 2012 Mar;27(3):657-63. doi: 10.3892/or.2011.1562. Epub 2011 Nov 24.

PMID:
22134540
45.

VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer.

Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY.

Clin Transl Oncol. 2011 Nov;13(11):805-8. doi: 10.1007/s12094-011-0737-3.

PMID:
22082645
46.

Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA.

PLoS One. 2011;6(7):e22469. doi: 10.1371/journal.pone.0022469. Epub 2011 Jul 25.

47.

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

Dirix LY, Van Dam PA, Prove AM, Vermeulen PB.

Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.

48.

Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies.

Thertulien R, Manikhas GM, Dirix LY, Vermorken JB, Park K, Jain MM, Jiao JJ, Natarajan J, Parekh T, Zannikos P, Staddon AP.

Cancer Chemother Pharmacol. 2012 Feb;69(2):341-50. doi: 10.1007/s00280-011-1697-6. Epub 2011 Jul 8.

49.

mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.

Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW.

Clin Cancer Res. 2011 Jun 1;17(11):3600-18. doi: 10.1158/1078-0432.CCR-11-0255. Epub 2011 Apr 19.

50.

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer.

Peeters DJ, Van den Eynden GG, van Dam PJ, Prové A, Benoy IH, van Dam PA, Vermeulen PB, Pauwels P, Peeters M, Van Laere SJ, Dirix LY.

Br J Cancer. 2011 Apr 26;104(9):1472-7. doi: 10.1038/bjc.2011.122. Epub 2011 Apr 5.

Supplemental Content

Loading ...
Support Center